Drawing for ETS EMERGING THERAPY SOLUTIONS

USPTO serial 88492279

ETS EMERGING THERAPY SOLUTIONS

Reviewed by CopyMark Law Group

Reg. 5960197Status 710
Filing date
Status date
Registration date
Jan 14, 2020
Examiner
CHHINA, KARANENDRA S
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with ETS EMERGING THERAPY SOLUTIONS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Garrett M. Weber

GARRETT M. WEBER BALLARD SPAHR LLP80 SOUTH 8TH STREETSUITE 2000MINNEAPOLIS, MN 55402

Goods and services

ClassDescriptionStatusFirst use
035Business management and consulting services for the health care industry, namely, business management of cell, gene and other complex medical therapies for health plans, health insurers, self-funded plans, and reinsurers; business management and administration in the field of healthcare, namely, development, creation and implementation of health care provider networks; business administration of cell, gene and other complex therapy programsSECTION 8 - CANCELLEDJun 13, 2019
036Financial consultation to healthcare providers, namely, providing assistance in obtaining reimbursement of health care expenses related to cell, gene and other complex therapiesSECTION 8 - CANCELLEDJun 13, 2019
044Consulting services in the field of medical care, namely, developing medical treatment policies related to cell, gene, and other complex therapies; medical information services related to cell, gene and other complex therapiesSECTION 8 - CANCELLEDJun 13, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 24, 2026C8..CANCELLED SEC. 8 (6-YR)—
Jan 14, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 14, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 29, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 29, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 9, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 23, 2019ALIEASSIGNED TO LIE—
Sep 18, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 18, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Sep 18, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 18, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 18, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 17, 2019DOCKASSIGNED TO EXAMINER—
Jul 10, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jul 9, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 1, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance